Silvia Gatti-McArthur co-edited a series on Dopaminergic Alterations in Schizophrenia

Schizophrenia is a disabling pathology with a lifetime prevalence of approximately 1% worldwide and the etio-pathological mechanism(s) remain elusive. New therapies are also needed for the cognitive and negative symptoms of the disease which appear central to functional outcomes and yet poorly served by current therapies. The interesting topic issue Dopaminergic alterations in schizophrenia co-edited by S Gatti-McArthur, Andrew Grottick PM Llorca, JC Martel, Carol Tamminga, and Mark Tricklebank is now completed. A final editorial introduces the 10 outstanding contributions and provides a synthesis of the current knowledge regarding dopaminergic alterations in schizophrenia. The issue is the result of the collaboration of 3 participating journals Frontiers in Pharmacology (neuropharmacology section), Frontiers in Neuroscience (Neuropharmacology section), and Frontiers in Psychiatry (schizophrenia section). Few recent related issues have also appeared in the same journals and are reviewed in the editorial. They provide an important complement to this read and highlight specific areas of scientific progress.